Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
150
resultados
Última actualización
04/10/2026 [07:42:00]
Resumen de: US20260297673A1
0000 Blood-based genome-wide DNA methylation profiles are utilized to develop a reliable test to diagnose irritable bowel syndrome (IBS) versus inflammatory bowel disease (IBD), celiac disease and other gastrointestinal diseases that mimic IBS. These methods provide a means to rule out IBS and rule-in active IBD or celiac disease, as well as to rule-out active IBD and celiac disease, and to rule-in IBS.
Resumen de: WO2025107068A1
It is provided a method of detecting inflammatory bowel disease (IBD) in a patient comprising the step of measuring in a sample of said patient protein expression from the sample, and determining from the measured expression the presence or absence in the patient of inflammatory bowel disease. The method comprises measuring the protein expression level measured of S100-A9, neutral ceramidase, serum albumin, chymotrypsin-C, protein S100-A4, alpha-1-acid glycoprotein 1, neprilysin, lactotransferrin, immunoglobulin lambda-like polypeptide 5, immunoglobulin heavy variable 4-28, protein S100-A8, chymotrypsin-like elastase family member 3A, IgGFc-binding protein, mucin-2, antithrombin-l 11, myeloblastin, zymogen granule membrane protein 16, annexin A2, glyceraldehyde-3-phosphate dehydrogenase, chloride anion exchanger, and/or a combination thereof.
Resumen de: WO2026196294A1
The present invention provides improved management of IBD treatment by anti-TNF-alpha antibodies comprising glycans having Neu5Ac instead of non-human Neu5Gc glycosylation or by antibodies in which Neu5Ac was added. The present invention further provides methods for monitoring levels of anti-glycan antibodies in IBD patients and prediction of development of secondary immune mediated inflammatory autoimmune diseases, mediated by these antibodies.
Resumen de: US20260285908A1
0000 Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
Resumen de: US20260275426A1
Embodiments of the disclosure encompass methods and compositions for treating and/or identifying subjects having Inflammatory Bowel Disease (IBD). In certain embodiments, methods include measuring taxa occurrence frequencies in at least one microbiome sample from a subject suspected or having or being at risk for having IBD when certain taxa are enriched in the microbiome and/or when certain taxa are deficient in the microbiome, and particularly upon classification of their microbiome based on a taxa enrichment profile. In certain embodiments, an individual is determined to be a suitable donor for fecal microbiota transplant or is determined not to be a suitable donor for FMT based on classification of the taxa profile of their microbiome.
Resumen de: US20260272993A1
The present invention relates generally to methods and compositions for treating and/or preventing an inflammatory bowel disease (IBD) and perianal fistulas, the method comprising the administration of therapeutic cells in the subject in need thereof.
Resumen de: AU2025228200A1
The present disclosure relates to dosage regimens for glucagon-like-peptide-2 (GLP-2) analogs, e.g., apraglutide, in a subject in need thereof, e.g., a subject with short bowel syndrome (SBS).
Resumen de: AU2026220293A1
Abstract The present invention relates to methods of immune modulation. In particular, the present invention relates to regulation of inflammation and immune responses by modulation of ABCF1. Modulation of ABCF1 may be useful in the treatment of sepsis, autoimmune diseases, cancer or infections. ug u g
Resumen de: AU2025237849A1
Methods of identifying a canine subject susceptible to inflammatory bowel disease, methods of treating or preventing inflammatory bowel disease in a canine subject, and compositions useful for treating or preventing inflammatory bowel disease in a canine subject are described herein.
Resumen de: US20260265828A1
Biomarkers that are indicative of the response to the therapy of the inflammatory bowel disease, including ulcerative colitis (UC) and Crohn's disease (CD), are described. Also described are probes capable of detecting the biomarkers and related methods and kits for predicting the response to the therapy of the inflammatory bowel disease.
Resumen de: WO2026185407A1
The present invention is directed to compositions, including post-biotic compositions, comprising cereal gruel fermented by Lactobacillus plantarum 299 and/or Lactobacillus plantarum 299v®. The compositions are useful for 5 treating diseases in human beings, including liver diseases, as well as gastrointestinal diseases and inflammatory conditions related to liver diseases. Disease treatment and treatment efficacies may be monitored based on the development in selected patient groups of one or more biomarkers, including intestinal fatty acid-binding protein (I-FABP) and C-reactive protein 10 (CRP).
Resumen de: US20260265841A1
In some embodiments, provided is a method for identifying a stool sample with an altered microbiome associated with IBD with disease above TI comprising the steps of: a) determining the relative abundance of a set of bacterial species in the stool sample; b) comparing the relative abundance of each bacterial species in the set of bacterial species from the individual with the relative abundance of each bacterial species in the set of bacterial species in a reference data set to generate a risk score; and c) determining the stool sample as having an altered microbiome associated with IBD with disease above the TI if the risk score is higher than a cutoff value. Other embodiments are described herein. In some embodiments, provided methods, kits, products and uses of compositions provide a cost-effective, non-invasive method to support clinical decision making, and hence to help improve disease management regarding disease above TI.
Resumen de: US2016060335A1
The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.
Resumen de: WO2026178656A1
It is provided a biodegradable gel mimetic matrix for cells seeding, the mimetic matrix composed of a functionalized alginate and a functionalized biodegradable polymer with at least one peptide, such as PEG. The PEG carries vinyl-sulfone groups that enable it to interact with the peptides and alginate. Alginate controls the gelation and stiffness of the mimetic matrix. It is further provided a method of culturing cells onto the matrix, providing a model to study epithelial cell behaviour toward a pathological state like inflammatory bowel disease (IBD) or cancer, like colorectal cancer.
Resumen de: WO2026182113A1
A method for predicting endoscopic activity of ulcerative colitis, the method comprising: step (a) for measuring the concentration of one or more substances selected from the group consisting of C9, CYTF, LBP, Gelsolin, a1-Microglobulin, Resistin, MMP-8, MMP-9, HPT, C4, IGFBP-2, C3, and BIN2 in a blood sample of a subject; and step (b) for determining endoscopic activity of ulcerative colitis in the subject on the basis of the concentration of the protein in the blood sample measured in step (a).
Resumen de: WO2020141608A1
The purpose of the present invention is to provide a test method and the like that is specific for ulcerative colitis and for primary sclerosing cholangitis. The present invention firstly provides a test method for ulcerative colitis, the test method being a detection step of detecting, in a sample and as an indicator of ulcerative colitis, an antibody that immunologically reacts with integrin αVβ6 and/or an antibody that immunologically reacts with integrin αVβ3. The present invention secondly provides a test method for primary sclerosing cholangitis, the test method being a detection step of detecting, in a sample and as an indicator of primary sclerosing cholangitis, an antibody that immunologically reacts with an antibody that immunologically reacts with integrin αVβ6 and/or integrin αVβ3.
Resumen de: WO2025120137A1
The present invention relates to the field of mucins and mRNA isoforms thereof, more in particular the use of mucins and mRNA isoforms in subjects suspected having an intestinal disorder. Provided herein is an in vitro method for determining the presence of barrier damage to the intestinal tract and/or prediction of therapy response and recovery thereto by determining the expression of at least 3 mRNA isoforms originating from genes selected from the list comprising: MUC1, MUC2, MUC3A, MUC4, MUC5AC, MUC5B, MUC6, MUC12, MUC12-AS1, MUC13, MUC16, MUC17, MUC19, MUC20 or an overlapping transcript or a pseudogene thereof.
Resumen de: US20260250768A1
The disclosure provides nucleic acid molecules, including cDNA, comprising an alteration that encodes a truncated human Single Immunoglobulin Interleukin-1 Receptor Related (SIGIRR) protein. The disclosure also provides isolated and recombinant human SIGIRR protein variants that comprise a truncation at a position corresponding to position 215. The truncation, and the nucleic acid molecules encoding this change, associate with early-onset inflammatory bowel disease (EO-IBD). The disclosure also provides methods for determining whether a subject has or has a risk of developing EO-IBD, based on the identification of such alterations in the nucleic acid molecules encoding SIGIRR.
Resumen de: US20260250767A1
The present disclosure generally relates to the treatment of subjects having IBD or at risk of developing IBD by administering an Indoleamine 2,3-Dioxygenase 2 (IDO2) agonist or a SMAD Family Member 2 (SMAD2) agonist to the subject.
Resumen de: WO2025085674A1
In one aspect, the present disclosure provides a method for selecting a subject having ulcerative colitis for treatment with ADS051, or a pharmaceutically acceptable salt thereof, the method comprising: (a) measuring MRP2 seRNA in a stool sample obtained from the subject; and (b) selecting the subject for treatment when the level of MRP2 seRNA in the stool sample exceeds a threshold value. In some embodiments, the subject has moderate or severe ulcerative colitis.
Resumen de: CN122631891A
0001 本发明公开了一种用于区分结直肠癌与结直肠腺瘤的标志物及其应用，涉及生物医学技术领域，标志物选自以下任一项：由SELL、CD177、ITGAL、OLR1、B2M、LAG3组成的外泌体表面驱动标志物；由TGM3、PSMB4、KRT80、KRT2、DSG1、CPOX、CPN1、SUB1、LSM2、RAB34、PZP、SERPINA5、HYDIN、PGLYRP1组成的内部核心蛋白；KRT80单指标标志物。本发明能够实现结直肠癌与结直肠腺瘤的检测。
Resumen de: CN122629194A
0001 本发明公开了一种间充质基质细胞治疗克罗恩病的肠道微生物标志物、产品及其应用，本发明提供的肠道微生物标志物包括丹毒丝菌目、粪杆菌属、丹毒丝菌科、芽孢杆菌纲、乳杆菌目、乳杆菌科、紧密乳杆菌属、厚壁菌门、鼠杆菌科、拟杆菌目、拟杆菌纲、拟杆菌门、梭菌纲、毛螺菌目、毛螺菌科、梭菌纲UCG‑014、颤螺菌目中的一种或多种。通过检测上述标志物的含量或丰度，可预测间充质基质细胞治疗克罗恩病的疗效。本发明还提供了基于上述标志物构建疗效预测模型的方法，得到疗效预测模型。本发明能够实现对间充质基质细胞治疗克罗恩病疗效的提前预测，具有良好的临床应用前景。
Resumen de: CN122628157A
本发明涉及一种与皮质醇小分子特异性结合的人工从头设计蛋白，所述蛋白质的氨基酸序列如SEQ ID NO:1所示。本发明通过深度学习方法，针对皮质醇分子的空间结构、疏水特征以及官能团分布，使用模型构建与其匹配的结合口袋，使设计蛋白能够通过疏水相互作用、氢键作用及空间构象互补等方式与皮质醇形成稳定结合。相比天然蛋白随机筛选方式，本发明可通过结构约束提高结合位点与目标分子的匹配程度，从而提升对皮质醇的识别特异性。
Resumen de: WO2026173915A1
Systems and methods for training machine learning models are described. The methods may comprise, e.g., receiving a first plurality of images of tissue specimens stained with a histochemical stain; receiving a second plurality of images of the tissue specimens stained with an immunohistochemical stain; aligning corresponding pairs of images; segmenting the aligned corresponding pairs of images to generate first and second pluralities of segmented images; mapping segments in each segmented image of the first plurality to corresponding segments in an image of the second plurality; and generating labeled image data by labeling segments in the images of the first plurality as exhibiting a specified cellular feature (or biomarker) based on detection of a signal associated with the immunohistochemical stain. In some instances, the labeled image data can be used to train a machine learning model for a digital pathology application, e.g., the evaluation of colitis severity.
Nº publicación: US20260243763A1 20/08/2026
Solicitante:
BOARD OF REGENTS OF THE UNIV OF NEBRASKA [US]
Board of Regents of the University of Nebraska
Resumen de: US20260243763A1
In various embodiments methods of distinguishing Crohn's disease from ulcerative colitis are provided. In certain embodiments the methods comprise determining, or causing to be determined, the level of IgG antibodies that bind a malondialdehyde-acetaldehyde adduct (MAA adduct) in a biological sample from a mammal, where an elevated level of said antibodies as compared to the average level found in a mammal with Crohn's disease is an indicator that the mammal has ulcerative colitis rather than Crohn's disease
BOPI
Sede Electrónica
